



Apersy

Value | Commercial | Access

March 2023 Market
Access news recap

READING LIST edition*

Evidence & Access



[The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price](#)

Digital & AI



[UK launches the developer information and support in its Launch of AI and Digital Regulations Service](#)

Value & Reimbursement



[G-BA regulates prescription & reimbursement of medical cannabis in serious illnesses: no additional requirements that go beyond the legally mandatory and binding regulation requirements \[GERMAN\]](#)

[NICE in England is developing a new proportionate approach to the technology appraisal processes. This will help increase capacity and allow to produce more guidance.](#)

Financing obesity treatments



[Covering new weight loss drugs could strain Medicare, policy experts warn](#)

[NICE recommended weight-loss drug to be made available in specialist NHS services](#)

For more updates on how payers think about value and evaluate health tech products, connect or get in touch



contact@apersy.com



www.apersy.com



www.linkedin.com/company/apersy/